|
|
|
|
|
|
|
|
|
|
ScienceDirect.com - Gynecologic Oncology - A clinical experience of single agent Bevacizumab in relapsing ovarian cancer
Highlights
►
The median time to progression in women with heavily treated recurrent
ovarian carcinoma treated with bevacizumab was 4 months.
► The most frequent adverse effect was arterial hypertension (62% of patients) and no intestinal perforation was reported.
► The PFS was marginally improved in patients who experienced severe arterial hypertension during the first month of therapy.
► The most frequent adverse effect was arterial hypertension (62% of patients) and no intestinal perforation was reported.
► The PFS was marginally improved in patients who experienced severe arterial hypertension during the first month of therapy.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.